FDA PMA
FDA Class 3
Approved
🇺🇸 United States
System, Colorectal Neoplasia, Dna Methylation And Hemoglobin Detection
PMA: P130017
·
Supplement: S042
·
Decision Aug 26, 2020
Classifications
1
FEI Numbers
11
Registration Numbers
11
Basic Information
- Device Name
- System, Colorectal Neoplasia, Dna Methylation And Hemoglobin Detection
- Trade Name
- Cologuard
- PMA Number
- P130017
- Supplement Number
- S042
- Device Class
- FDA Class 3
- Product Code
- PHP
- Generic Name
- System, colorectal neoplasia, DNA methylation and hemoglobin detection
- Medical Specialty
- Unknown
- Advisory Committee
- Pathology
- Decision
- Approved
- Decision Code
- APPR
- Decision Date
- August 26, 2020
- Date Received
- May 27, 2020
- Supplement Type
- Normal 180 Day Track No User Fee
- Supplement Reason
- Postapproval Study Protocol
- Expedited Review
- N
Advisory Committee Statement
Approval of the clinical protocol titled A Real-World Study of Patients Under the Age of 50 Screened for Colorectal Cancer (CRC) Using Cologuard® in the U.S. Tidal, for the post-approval study (PAS) protocol.
Classifications
This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.
| Product Code | Device Name | Device Class | Medical Specialty |
|---|---|---|---|
| PHP | System, Colorectal Neoplasia, Dna Methylation And Hemoglobin Detection | FDA class 3 | Unknown |